Moderna gets $50M investment for Ebola vaccine candidate

Moderna has secured a $50 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its experimental Ebola vaccine targeting the Bundibugyo strain, which is currently causing outbreaks in the Democratic Republic of Congo. This funding aims to support the development and initial clinical testing of the vaccine, with the potential to scale up manufacturing if early trial results are promising. This investment underscores the urgent need for effective vaccines in combating deadly viruses and highlights the global effort to prepare for future epidemics.